BD acquires Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to enhance smart connected care solutions
Acquiring Company
Bard
Acquired Company
Edwards Lifesciences
United StatesIrvineManufacturingHealth CareManufacturingBiotechnologyHealthcareHealth CareArtificial IntelligenceMedicalMedical DeviceDescription
BD (Becton, Dickinson and Company) has entered into a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD’s portfolio of smart connected care solutions and establish its position as an advanced monitoring technology leader.
Quick answer
Bard is acquiring Edwards Lifesciences for $4.2 billion, announced June 3, 2024. Bard is based in United States.
- How much did Bard pay for Edwards Lifesciences?
- The reported deal value is $4.2 billion.
- What does Bard do?
- Bard is a leading provider of medical technologies, including devices for urology, oncology, and vascular medicine.
- Where are Bard and Edwards Lifesciences based?
- Bard is based in United States. Edwards Lifesciences is based in Irvine, California, United States.
- Who are the decision-makers at Bard?
- Fundz holds 2 contacts at Bard. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AA Medical completes acquisition of Surgical Product Solutions, forming strategic partnership (July 11, 2024)
- GE HealthCare to acquire clinical artificial intelligence business from Intelligent Ultrasound Group PLC (July 18, 2024)
- Eli Lilly and Company acquires manufacturing facility from Nexus Pharmaceuticals to expand U.S. capacity (April 22, 2024)
- Merck completes acquisition of EyeBio to diversify its late-stage pipeline (July 12, 2024)
- HEALWELL AI finalizes acquisition of VeroSource Solutions and BioPharma Services to expand healthcare technology capabilities (July 2, 2024)
- Healthcare Holding Schweiz AG completes acquisition of MCM Medsys AG to expand its product portfolio (April 25, 2024)
Who to call at Bard, and when
When Bard changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Bard raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bard, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bard. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bard makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Edwards Lifesciences?
Edwards Lifesciences was acquired by Bard, based in United States. The deal was reported on June 3, 2024. Bard is a leading provider of medical technologies, including devices for urology, oncology, and vascular medicine. Bard is privately held and operates in Manufacturing.
When did Bard acquire Edwards Lifesciences?
Bard's acquisition of Edwards Lifesciences was reported on June 3, 2024. BD (Becton, Dickinson and Company) has entered into a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Edwards Lifesciences do?
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. It is privately held, operating in Manufacturing, and is based in Irvine.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.